![](/f/f/edb99351d8b637542eaefa34ca48e89b.jpg)
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
1/2024
vol. 99 abstract:
Review paper
Lactobacillus rhamnosus for treating irritable bowel syndrome in children – a systematic review with meta-analysis
Joanna Tarnoruda
1
,
Marek Ruszczyński
1
,
Jakub Żółkiewicz
2
,
Luiza Sulej
1
,
Barbara Bożek
1
,
Aleksandra Hoffmann
1
Pediatr Pol 2024; 99 (1): 53-60
Online publish date: 2024/03/09
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
The objective of the study was to systematically assess whether the oral probiotic Lactobacillus rhamnosus (LGG) improves symptoms of irritable bowel syndrome in children. Four randomised clinical trials met the inclusion criteria, a total of 252 patients. Success of treatment was reported in 50 out of 82 patients (58.82%) from the LGG group, compared with 28 from 82 (34.14%) in the placebo group (p = 0.05). The number of pain episodes was lower in the LGG group compared with the placebo group (n = 117, 95% CI: 1.50 [–2.03; –0.97], p < 0.05). The use of LGG resulted in a decrease in the perception of pain intensity in the study population overall (n = 219, 95% CI: –0.61 [–1.13; –0.09], p < 0.05). A higher dosage of LGG was less effective than a lower dosage in improving the overall treatment success (p = 0.05). The dosage of LGG was not statistically significant in improving pain severity (p = 0.12).
keywords:
Lactobacillus rhamnosus, microbiota, probiotic, irritable bowel syndrome |